Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Clearmind Medicine (CMND) has appointed professors Wim van den Brink and Gabriele Fischer to the company’s scientific advisory board
  • Professor Wim van den Brink, M.D., Ph.D., is a professor of addiction psychiatry at the Academic Medical Center of the University of Amsterdam
  • Professor Gabriele Fischer, M.D., is a professor of addiction research and treatment and medical director at the Department of Psychiatry & Psychotherapy at the Medical University of Vienna
  • Clearmind is a psychedelic pharmaceutical biotech company
  • Clearmind Medicine Inc. (CMND) opened trading at C$0.80 per share

Clearmind Medicine (CMND) has appointed professors Wim van den Brink and Gabriele Fischer to the company’s scientific advisory board.

Professor Wim van den Brink, M.D., Ph.D., is a professor of addiction psychiatry at the Academic Medical Center of the University of Amsterdam and a recognized expert in the neurobiology and pharmacological treatment of substance use disorders and behavioural addictions. 

Professor Gabriele Fischer, M.D., is a professor of addiction research and treatment and medical director of the Addiction Clinic at the Department of Psychiatry & Psychotherapy at the Medical University of Vienna. Gabriele has acted as principal or cooperating investigator on international epidemiological clinical and psychopharmacological studies in the field of substance use disorder and nonsubstance-related addictions. 

Adi Zuloff-Shani, Ph.D., CEO of Clearmind, commented on the appointments.
“Professor van den Brink and professor Fischer have both made substantial contributions to the field of substance abuse and related behaviors, advancing the way we understand and treat addiction. There are few scientists in the world with their breadth of knowledge and experience, and we are delighted to welcome them to our scientific advisory board.”

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.

Clearmind Medicine Inc. (CMND) opened trading at C$0.80 per share.

More From The Market Herald

" BioVaxys (CSE:BIOV) files patent for pan-sarbecovirus vaccine

BioVaxys Technology (BIOV) has filed a provisional patent application for its viral antigen vaccine platform.

" Datametrex (TSXV:DM) launches smartphone health app

Datametrex AI (DM) subsidiary Medi-Call MD has officially launched a closed beta test for its Medi-Call health app.
Avicanna Inc - CEO, Aras Azadian.

" Avicanna (TSX:AVCN) closes private placement

Avicanna (AVCN) has closed a non-brokered private placement for gross proceeds of approximately $3.9 million.

" Small Pharma (TSXV:DMT) doses first patient in trial

Small Pharma Inc. (DMT) has dosed the first patient of its Phase IIa clinical trial for its lead N,N-dimethyltryptamine candidate, SPL026.